Skip to content
Search

Latest Stories

PDA cancels national conference in coronavirus response

The PDA today announced that it will be cancelling four events including its national conference on account of the ongoing coronavirus situation.

The national conference was scheduled to held in Birmingham on 28-29 March.


Other events cancelled include the pre-registration trainee ‘Finishing First’ courses due in Birmingham on 28-29 March, Manchester on 19 April and London on 26 April.

“When the time comes, we want as many pharmacists as possible to be available to focus on the national efforts to manage the crisis,” PDA chairman Mark Koziol said.

“We fully expect that in these extra-ordinary times, many will need to be involved in extra-ordinary measures and even unusual front-line activities.”

The association added that it wanted to support the reduction of non-essential travel and large-scale public gatherings to manage the spread of the virus.

As of 9am today, 32,771 people have been tested in the UK for the virus, of which 798 were confirmed as positive. The death toll stands at 10.

Prime Minister Boris Johnson yesterday moved Britain‘s response to the outbreak to the so-called “delay phase”, aimed at putting off the peak until the summer months, ending a phase of outright containment.

The PDA said it will disseminate various initiatives that were to be launched at the national conference to members in other ways.

Regarding the Finishing First sessions, the PDA said it is already looking into alternative ways in which the exam preparation can be supported.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less